Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EfgaDem
2023-510216-39-00Phase 2Authorised
- Sponsor
- German Center for Neurodegenerative Diseases
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune dementia comparing Efgartigimod with Placebo (2 arms). Primary endpoint: Cognitive impairment (primary). Planned start Jun 2025; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune dementia
Beyond the preview
Go deeper on 2023-510216-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510216-39-00.